EUVIMEDEUVIMED entdecken
Crossref

Shorter time to initiation of biologic therapy in the setting of a hidradenitis suppurativa specialty clinic

Niamh Kearney iD, Sarah O'Donohoe, Rosalind Hughes, Brian Kirby iD

Clinical and Experimental Dermatology · 2023

DOI: 10.1093/ced/llad191 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Dermatology, 2023. Verfasst von Niamh Kearney und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, St Vincent's University Hospital Dublin, Dublin, Ireland. Hauptthemen laut MEDLINE: Hidradenitis Suppurativa, Biological Products. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 10 Literaturangaben. Gefördert von: City of Dublin Skin and Cancer Hospital Charity.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hidradenitis suppurativa (HS) is a chronic condition with a significant psychological and physical burden but a paucity of effective treatments. Early intervention with adalimumab improves disease outcomes. Two previous studies in Denmark and Northern Ireland have identified a time of 8.2 and 2.9 years, respectively, from first HS systemic/dermatology consultation to commencing a biologic. We aimed to evaluate the time from disease onset and from first specialty HS clinic review to the initiation of biologic therapy. We retrospectively reviewed 34 patients on biologic treatment for HS. The mean diagnostic delay was 12.4 years. The mean time from disease onset to biologic initiation was 14.8 years. Prior to a biologic, patients received a median of 3.3 treatments from the specialty HS clinic. The median time to biologic from first presentation at the specialty HS clinic was 1 year. This is shorter than the therapeutic delay reported in dermatology clinics in Denmark and Northern Ireland, providing evidence on the importance of specialized HS treatment. However, to make an impact with specialized HS care and earlier biologic initiation, diagnostic delay needs to be reduced.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hidradenitis SuppurativaBiological ProductsHumansRetrospective StudiesDelayed DiagnosisAdalimumabBiological TherapySeverity of Illness Index

Substanzen

AdalimumabBiological Products

Autor:innen und Institutionen

  • Department of Dermatology, St Vincent's University Hospital Dublin, Dublin, Ireland.
  • School of Medicine, University College Dublin, Dublin, Ireland.
  • Charles Institute of Dermatology, University College Dublin, Dublin, Ireland.

ORCID-Profile: Niamh Kearney, Brian Kirby

Förderung

  • City of Dublin Skin and Cancer Hospital Charity

Zitieren

APA

Kearney, N., O'Donohoe, S., Hughes, R., & Kirby, B. (2023). Shorter time to initiation of biologic therapy in the setting of a hidradenitis suppurativa specialty clinic. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llad191

Vancouver

Kearney N, O'Donohoe S, Hughes R, Kirby B. Shorter time to initiation of biologic therapy in the setting of a hidradenitis suppurativa specialty clinic. Clinical and Experimental Dermatology. 2023. doi:10.1093/ced/llad191

BibTeX
@article{Kearney2023,
  author = {Kearney, Niamh and O'Donohoe, Sarah and Hughes, Rosalind and Kirby, Brian},
  title = {Shorter time to initiation of biologic therapy in the setting of a hidradenitis suppurativa specialty clinic},
  journal = {Clinical and Experimental Dermatology},
  year = {2023},
  doi = {10.1093/ced/llad191}
}
Kostenlos starten →